• Thu, March 3, 2022
Joel Beatty Upgraded (VIR) to Hold and Decreased Target to $28 on, Mar 3rd, 2022
Joel Beatty of Baird, Upgraded "Vir Biotechnology, Inc." (VIR) to Hold and Decreased Target from $36 to $28 on, Mar 3rd, 2022.
Joel has made no other calls on VIR in the last 4 months.
There is 1 other peer that has a rating on VIR. Out of the 1 peers that are also analyzing VIR, 0 agree with Joel's Rating of Hold.
This is the rating of the analyst that currently disagrees with Joel
- Patrick Trucchio of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $300 on, Tuesday, December 21st, 2021
